A Pharmaceutical Care Program to Improve Adherence to Statin Therapy: A Randomized Controlled Trial

Abstract

Spanish

French

Background:

Despite the well-known beneficial effects of statins, many patients do not adhere to chronic medication regimens.

Objective:

To implement and assess the effectiveness of a community pharmacy-based pharmaceutical care program developed to improve patients' adherence to statin therapy.

Methods:

An open-label, prospective, randomized controlled trial was conducted at 26 community pharmacies in the Netherlands. New users of statins who were aged 18 years or older were randomly assigned to receive either usual care or a pharmacist intervention. The intervention consisted of 5 individual counseling sessions by a pharmacist during a 1-year period. During these sessions, patients received structured education about the importance of medication adherence, lipid levels were measured, and the association between adherence and lipid levels was discussed. Adherence to statin therapy was assessed as discontinuation rates 6 and 12 months after statin initiation, and as the medication possession ratio (MPR), and compared between the pharmaceutical care and usual care groups.

Results:

A total of 899 subjects (439 in the pharmaceutical care group and 460 in the usual care group) were evaluable for effectiveness analysis. The pharmaceutical care program resulted in a significantly lower rate of discontinuation within 6 months after initiating therapy versus usual care (HR 0.66, 95% CI 0.46 to 0.96). No significant difference between groups was found in discontinuation at 12 months (HR 0.84, 95% CI 0.65 to 1.10). Median MPR was very high (>99%) in both groups and did not differ between groups.

Conclusions:

These results demonstrate the feasibility and effectiveness of a community pharmacy–based pharmaceutical care program to improve medication adherence in new users of statins. Frequent counseling sessions (every 3 months) are necessary to maintain the positive effects on discontinuation. Although improvements are modest, the program can be applied easily to a larger population and have a large impact, as the interventions are relatively inexpensive and easy to implement in clinical practice.

Keywords

adherence cardiovascular drugs lipids pharmaceutical care

Get full access to this article

View all access options for this article.

References

Colivicc

, Bassi

, Santini

, Caltagirone

. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38:2652–7. DOI 10.1161/STROKEAHA.107.487017

Blackburn

, Dobson

, Blackburn

, Wilson

, Stang

, Semchuk

. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005; 21:485–8.

Jackevicius

, Mamdani

, Tu

. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462–7.

Perreault

, Blais

, Dragomir

. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005; 61:667–74. DOI 10.1007/s00228-005-0980-z

Council of Europe, Committee of Ministers. Resolution ResAP(2001)2 concerning the pharmacist's role in the framework of health security. https://wcd.coe.int/ViewDoc.jsp?id=193721&BackColorInternet=9999CC&BackColorIntranet=FFBB55&BackColorLogged=FFAC752001 (accessed 2009 Nov 12).

World Health Organization (WHO). The role of the pharmacist in the health care system. http://apps.who.int/medicinedocs/es/d/Jh2995e/1.9.html 1994 (accessed 2009 Nov 12).

Bozovich

, Rubino

, Edmunds

. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000; 20:1375–83.

Ellis

, Carter

, Malone

. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000; 20:1508–16.

Faulkner

, Wadibia

, Lucas

, Hilleman

. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000; 20:410–6.

10.

Lee

, Grace

, Taylor

. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296:2563–71. DOI 10.1001/jama.296.21.joc60162

11.

Nietert

, Tilley

, Zhao

. Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care 2009; 47:32–40. DOI 10.1097/MLR.0b013e3181808c17

12.

Nola

, Gourley

, Portner

. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc 2000; 40:166–73.

13.

Paulós

, Nygren

, Celedón

, Cárcamo

. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother 2005; 39:939–43. DOI 10.1345/aph.1E347

14.

Peterson

, Fitzmaurice

, Naunton

, Vial

, Stewart

, Krum

. Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. J Clin Pharm Ther 2004; 29:23–30.

15.

Poston

, Loh

, Dunham

. The medication use study. Can Pharm J 1998; 131:31–8.

16.

Rehring

, Stolcpart

, Sandhoff

, Merenich

, Hollis

Jr . Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg 2006; 43:1205–10. DOI 10.1016/j.jvs2006.02.019

17.

Vrijens

, Belmans

, Matthys

, de Klerk

, Lesaffre

. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 2006; 15:115–21.DOI 10.1002/pds.1198

18.

Benner

, Tierce

, Ballantyne

. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22(suppl 3):13–23.

19.

Buurma

, Bouvy

, De Smet

, Floor-Schreudering

, Leufkens

, Egberts

. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008; 33:17–23. DOI 10.1111/j.1365-2710.2008.00878.x

20.

Ministerie van Volksgezondheid, Welzijn en Sport. Wijziging Regeling farmaceutische hulp 1996. Dutch. https://zoek.officielebekendmakingen.nl/stcrt-1999-140-p7-SC19840.html (accessed 2010 Jul 26).

21.

Friedewald

, Levy

, Fredrickson

. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.

22.

Lekkerkerker

, Kanis

, Alsayed

. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007; 18:1311–7. DOI 10.1007/s00198-007-0410-4

23.

Van Wijk

, Klungel

, Heerdink

, de Boer

. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006; 59:11–7. DOI 10.1016/j.jclinepi.2005.05.005

24.

Gardarsdottir

, Souverein

, Egberts

, Heerdink

. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 2010; 63:422–7. DOI 10.1016/j.jclinepi.2009.07.001

25.

Herings

RMC

, Leufkens

HGM

, Heerdink

, Klungel

, Breekveldt-Postma

. Chronic pharmacotherapy forever. PHARMO report 2002. http://www.pharmo.nl/pdf/reports/Chronic%20Pharmacotherapy%20Forever.pdf (accessed 2009 Oct 19).

26.

World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2010. http://www.whocc.no/filearchive/publications/2010guidelines.pdf (accessed 2009 Oct 19).

27.

Penning-van Beest

, Termorshuizen

, Goettsch

, Klungel

, Kastelein

, Herings

. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007; 28:154–9. DOI 10.1093/eurheartj/eh1391

28.

Thomas

, Van der Weijden

, Van Drenth

, Haverkort

AFM

, Hooi

, Van der Laan

. NHG-Standaard Cholesterol. Dutch. Huisarts Wet 1999; 42:406–17.

29.

Dutch Institute for Healthcare Improvement CBO. Behandeling en preventie van coronaire hartziekten door verlaging van de plasmacholesterol-concentratie. Dutch. Consensus Cholesterol tweede herziening, 1998.

30.

McGinnis

, Olson

, Magid

. Factors related to adherence to statin therapy. Ann Pharmacother 2007; 41:1805–11. DOI 10.1345/aph.1K209

31.

Bouvy

, Heerdink

, Urquhart

, Grobbee

, Hoes

, Leufkens

. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail 2003; 9:404–11.

32.

Hamann

, Weimar

, Glahn

, Busse

, Diener

. Adherence to secondary stroke prevention strategies—results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15:282–8. DOI 10.1159/000069490

33.

White

. Uses and limitations of randomization-based efficacy estimators. Stat Methods Med Res 2005; 14:327–47.

34.

Catalan

, LeLorier

. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3:417–26. DOI 10.1046/j.1524-4733.2000.36006.x

35.

Caspard

, Chan

, Walker

. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005; 27:1639–46. DOI 10.1016/j.clinthera.2005.10.005

36.

Poluzzi

, Strahinja

, Lanzoni

. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008; 64:425–32. DOI 10.1007/s00228-007-0428-8

37.

Huser

, Evans

, Berger

. Medication adherence trends with statins. Adv Ther 2005; 22:163–71.

38.

Mann

, Allegrante

, Natarajan

, Halm

, Charlson

. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007; 21:311–6.

39.

Schwed

, Fallab

, Burnier

. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999; 39:402–9.

40.

McClure

, Valuck

, Glanz

, Hokanson

. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007; 16:132–43. DOI 10.1002/pds.1341

41.

Hewitt

, Torgerson

, Miles

. Individual allocation had an advantage over cluster randomization in statistical efficiency in some circumstances. J Clin Epidemiol 2008; 61:1004–8. DOI 10.1016/j.jclinepi.2007.12.002

42.

Torgerson

. Contamination in trials: is cluster randomisation the answer? BMJ 2001; 322:355–7.

43.

Puffer

, Torgerson

, Watson

. Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ 2003; 327:785–9. DOI 10.1136/bmj.327.7418.785